Benlysta SQ (belimumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		_ MEMBER'S FIRST NAM	MEMBER'S FIRST NAME:	
	g., chart notes or lab data, to		additional documentation that is request). Information contained in	
			URGENT	
MEMBER INFORMATION		FIDOT ALABAT		
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:	
STREET ADDRESS:				
CITY:		STATE: ZIP C	STATE: ZIP CODE:	
PATIENT INSURANCE ID NU	MBER:			
IF YOU ARE NOT THE PATIENT OR THE PRESC FOLLOWING LINK: PRIMETHERAPEUTICS.COI	CRIBER, YOU WILL NEED TO SUBMIT A PHI DI M/NOPP PRESENTATIVE (IF APPLICABI	ISCLOSURE AUTHORIZATION FORM WITH		
AUTHORIZED REPRESENTAT				
PRESCRIBER INFORMATION LAST NAME:	V	FIRST NAME:		
LAST IVAIVIE:		TINOTIVAIVIE.	FIRST IVAIVIE.	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:	
STREET ADDRESS:		·		
CITY:		STATE: ZIP C	STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERS	OFFICE CONTACT PERSON:	
		1		
MEDICATION OR MEDICAL	DISPENSING INFORMATION	N		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:	
NEW THERAPY DURATION OF THERAPY (SP	RENEWAL PECIFIC DATES):	IF RENEWAL: DATE THI	ERAPY INITIATED:	

Prime

Continued on next page.

Benlysta SQ (belimumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
 □ Systemic lupus erythematosus (SLE) WI □ Systemic lupus erythematosus WITH act □ Other DiagnosisICD-10 (tive Lupus nephritis	
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
Clinical Information:	nation with a clinical trial? Yes No	
Is the patient's SLEDAI (SLE Activity In	ndex) score greater than or equal to 6?	□ Yes □ No
antibodies?* □ Yes □ No *Please s		•
Does the patient have severe lupus k creatinine greater than 2.5 mg/dL)?	idney disease (proteinuria greater than ☐ Yes ☐ No	6 g/24 hrs or equivalent OR serum
Does the patient have severe CNS (ce	ntral nervous system) lupus? 🗆 Yes 🗅	No
Select if the patient has tried the follo	_	
□ Non-steroidal anti-inflammatory dr□ An anti-malarial (Plaquenil and/or		
□ A corticosteroid	nyaroxyemoroqume,	
☐ An immunosuppressive (azathiopri	ne, mycophenolate, methotrexate)	
*Please submit documentation.		
Does the patient have active biopsy-p	proven lupus nephritis? Yes No *	Please submit documentation.
Does patient have a urinary protein-t *Please submit chart notes with lab r	o-creatinine ratio equaling 1 or greater? esults.	? 🗆 Yes 🗆 No
Is patient's lupus nephritis ISN/RPS control pathology report, which documents t	lass III, class IV, or class V?	*Please submit chart notes with
Does the patient's estimated GFR equipmentation with lab report.	ual 30 ml/min/1.73m ² or greater? □ Ye	s □ No *Please submit chart



Benlysta SQ (belimumab) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
Has patient failed BOTH cyclophosphamide documentation.	AND mycophenolate induction therapy? ☐ Yes ☐ No *Please submit
Are there any other comments, diagnoses, s physician feels is important to this review?	symptoms, medications tried or failed, and/or any other information the
Please note: Not all drugs/diagnosis are cover information is received.	ered on all plans. This request may be denied unless all required
•	ided is true and accurate to the best of my knowledge. I understand that is designees may perform a routine audit and request the medical of the information reported on this form.
Prescriber Signature or Electronic I.D. Verific	cation: Date:
you are not the intended recipient, you are hereby not	ying this transmission contain confidential health information that is legally privileged. If tified that any disclosure, copying, distribution, or action taken in reliance on the contents eceived this information in error, please notify the sender immediately (via return FAX) uments.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

